Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. we hope you enjoy reading it.

1. The National Medical Commission (NMC) has reportedly not initiated any action against 30 doctors involved in a pharma freebies case. An RTI response reveals that the Department of Pharmaceuticals has not directed action, despite earlier findings of violations by the pharmaceutical company sponsoring lavish trips.
Source: bit.ly/44xs6e4

2. The Indian Pharmacopoeia Commission (IPC) has announced changes to certain monograph titles and synonyms in the upcoming Indian Pharmacopoeia (IP) 2026 which is effective from July 2026. Manufacturers have been advised to assess the impact on existing products and start taking necessary steps to update the label.
Source: bit.ly/4dtuq8p

3. India’s Ministry of Health has reportedly raised concerns that only a small fraction of small and medium-sized pharmaceutical companies have applied to the government for an extension of the timeline to comply with the Revised Good Manufacturing Practices (GMP) under Schedule M and to submit their facility upgradation plans. With the 12th May 2025 deadline approaching, state health secretaries have been asked to coordinate with local manufacturers and ensure timely compliance.
Source: bit.ly/4ka44u3

4. The Government of Odisha has reportedly announced plans to draft a state-wide mental health policy, including early intervention frameworks and counselling centres, to address rising mental health issues particularly among vulnerable groups such as youth and the elderly
Source: bit.ly/44peMIy

5. The European Medicines Agency (EMA) has officially recognized suicidal thoughts as a potential side effect of a medication commonly used to treat male pattern baldness. While the EMA maintains that the benefits of the drug continue to outweigh the risks, it has mandated that all 1 mg packages include a patient card highlighting these risks.
Source: bit.ly/3SgZLBr

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. India’s National Pharmaceutical Pricing Authority (NPPA) in public interest has approved 50% increase of ceiling price of eleven scheduled formulations of eight drugs from the current ceiling prices along with annual price increase as per the Wholesale Price Index (WPI) in April. This comes as a recommendation from the Inter-Ministerial Committee.
Source: bit.ly/3zOtSKV

2. Income Tax Appellate Tribunal (ITAT) of Ahmedabad has upheld the disallowance of amount claimed by a leading pharmaceutical company relating to promotional activities for doctors like accommodation, freebies etc and declared it as inadmissible for tax deductions. The activities were claimed as marketing tools rather than business necessities
Source: bit.ly/4eZ8fH7

3. India’s Central Drug Authority (CDSCO) along with National Regulatory Authority of India (NRA) and affiliated institutions after an evaluation by global experts have satisfied the WHO’s requirements for a functional vaccine regulatory system. Safety, efficacy, and quality are three basic parameters for the assessment of vaccines.
Source: bit.ly/4eJmn6S

4. The National Council for Clinical Establishments (NCCE) has recommended to allow the physiotherapists to own and run the clinics as per the amendment proposed in the Clinical Establishments (CE) Act, 2010. The decision comes as a relief to the physiotherapists and their organizations, which has been fighting legally to attain its right to own and run a clinic, which was not allowed as per the Act notified in 2010.
Source: bit.ly/3BMLs2s

5. The Directorate General of Foreign Trade (DGFT), under the Ministry of Commerce & Industry, has issued a Trade Notice to give clarification on the import and re-import provisions for “Exhibits and Samples” that are exported for display or exhibition purposes. This move is expected to support businesses and industries, including the pharmaceutical industry participating in both domestic and foreign exhibitions to facilitate effortless import or re-import of goods for exhibition or display without imposing further bureaucratic obstacles.
Source: bit.ly/4h7x9FD